Current report
Open the filing on sec.gov
Oric Pharmaceuticals, Inc. (ORIC)
Nasdaq: ORIC · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2019
The companyfiscal 2025, as filed
Revenuen/a
Net income-$129M-1.3%
Earnings per share$-1.47+19.7%
Operating cash flow-$111M+1.5%
Cash$46.2M-22.9%
Debtn/a
Shareholders’ equity$384M+58.1%
Shares, diluted87.8M+25.9%
Return on equity-33.7%
The recordfrom its filings
Filings in 202649
Newest filingOct 23 · 8-K
Annual reportFeb 23, 2026
Quarterly reportAug 3, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$3.0M
Insider buys, 12 months$0.00
Patents granted18
Filer categoryNon-accelerated filer
Trailing twelve months to Jun 2026Net income -$140MCash from operations -$112Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.